Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-17
    E.g., 2018-11-17

Articles

Pages

8098 items
10:56 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report. ICER said that the...
9:10 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Michigan to begin talks with drug manufacturers for value-based deals

With a stamp of approval from CMS on Nov. 14, Michigan joins Oklahoma as one of the only two states with the agency's OK to negotiate Medicaid outcomes-based pricing agreements with drug manufacturers. "Michigan’s waiver will...
9:10 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

NICE backs Novartis' Kymriah in acute lymphoblastic leukemia

U.K.'s NICE recommended in final guidance on Nov. 15 that CAR T therapy Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) for use through the Cancer Drug Fund in patients under 25 with relapsed or refractory...
11:15 AM, Nov 09, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

NICE recommends Jazz's Vyxeos for AML

The U.K.'s NICE issued a final appraisal determination (FAD) recommending Vyxeos daunorubicin/cytarabine to treat adults with newly diagnosed therapy-related acute myelogenous leukemia (AML) or AML with myelodysplasia-related changes. Vyxeos is a liposomal formulation of daunorubicin and...
10:36 AM, Nov 09, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
10:24 AM, Nov 09, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran...
10:00 AM, Nov 09, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

MorphoSys shares jump amid Tremfya guidance, MOR208 data

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) shares rose Nov. 6 after the company said in its 3Q18 earnings that plaque psoriasis drug Tremfya guselkumab could generate 2018 royalties at the upper end of the biotech's previous guidance....
9:57 AM, Oct 26, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

NICE recommends against abemaciclib for untreated breast cancer

The U.K.'s NICE issued draft guidance recommending against the use of Verzenio abemaciclib from Eli Lilly and Co. (NYSE:LLY) in combination with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer. NICE said...
9:46 AM, Oct 26, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Amgen drops Repatha list price by 60% to improve access for Medicare patients

Amgen Inc. (NASDAQ:AMGN) will reduce the U.S. list price of cardiovascular disease and hyperlipidemia drug Repatha evolocumab by 60% to improve access for Medicare patients, bringing it in line with the current rebate offered to...
11:02 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Oct. 17. The PBM gave the nod to Aimovig erenumab-aooe from...

Pages